Status:
COMPLETED
Nebulized Ceftazidime and Amikacin in Ventilator Associated Pneumonia
Lead Sponsor:
Groupe Hospitalier Pitie-Salpetriere
Conditions:
Pneumonia
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Pseudomonas aeruginosa is one of the major causative microorganisms of ventilator-associated pneumonia often resistant to antibiotics. In experimental models, nebulization of antibiotics delivers high...
Eligibility Criteria
Inclusion
- Male or female \>18 years old, ventilator associated pneumonia caused by pseudomonas aeruginosa
- Written informed consent provided by the relatives
Exclusion
- Pseudomonas aeruginosa resistant to ceftazidime and amikacin
- Pseudomonas aeruginosa pneumonia associated with other infections requiring intravenous treatment
- Severe septic shock and severe hypoxemia
- Allergy to ceftazidime or amikacin
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT00786305
Start Date
October 1 2004
End Date
November 1 2008
Last Update
November 6 2008
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Intensive care unit, Department of anesthesiology, La pitie-Salpetriere hospital
Paris, France, 75013